we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
Company profile
Ticker
PBYI
Exchange
Website
CEO
Alan H. Auerbach
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
INNOVATIVE ACQUISITIONS CORP
SEC CIK
Corporate docs
Subsidiaries
Puma Biotechnology B.V. ...
IRS number
770683487
PBYI stock data
Latest filings (excl ownership)
8-K
Other Events
19 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Puma Biotechnology Reports Fourth Quarter and Full Year
29 Feb 24
8-K
Regulation FD Disclosure
18 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Puma Biotechnology Reports Third Quarter 2023 Financial Results
2 Nov 23
8-K
Regulation FD Disclosure
26 Sep 23
8-K
Amendments to Articles of Incorporation or Bylaws
18 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Puma Biotechnology Reports Second Quarter Financial Results
3 Aug 23
Transcripts
PBYI
Earnings call transcript
2023 Q4
29 Feb 24
PBYI
Earnings call transcript
2023 Q3
2 Nov 23
PBYI
Earnings call transcript
2023 Q2
3 Aug 23
PBYI
Earnings call transcript
2023 Q1
4 May 23
PBYI
Earnings call transcript
2022 Q4
2 Mar 23
PBYI
Earnings call transcript
2022 Q3
3 Nov 22
PBYI
Earnings call transcript
2022 Q2
7 Aug 22
PBYI
Earnings call transcript
2022 Q1
6 May 22
PBYI
Earnings call transcript
2021 Q4
4 Mar 22
PBYI
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
SC 13G
Frazier Life Sciences Public Fund, L.P.
29 Mar 24
4
ALAN H AUERBACH
19 Mar 24
4
Alvin F Wong
14 Feb 24
4
MAXIMO F NOUGUES
14 Feb 24
4
Jeffrey Jerome Ludwig
14 Feb 24
4
ALAN H AUERBACH
14 Feb 24
4
DOUGLAS M HUNT
14 Feb 24
SC 13G/A
Camber Capital Management LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
ACORN BIOVENTURES, L.P.
6 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
62.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 73 |
Opened positions | 7 |
Closed positions | 5 |
Increased positions | 20 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 51.30 bn |
Total shares | 30.19 mm |
Total puts | 70.50 k |
Total calls | 268.10 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Camber Capital Management | 4.24 mm | $11.14 mm |
Vanguard | 3.77 mm | $9.92 bn |
Millennium Management | 3.08 mm | $8.11 bn |
Integrated Core Strategies | 2.00 mm | $7.22 mm |
Acadian Asset Management | 1.86 mm | $4.88 mm |
Athyrium Capital Management | 1.79 mm | $4.71 bn |
Renaissance Technologies | 1.73 mm | $4.54 bn |
Eversept Partners | 1.68 mm | $4.42 bn |
Acorn Bioventures | 1.59 mm | $5.50 mm |
BLK Blackrock | 1.48 mm | $3.88 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Auerbach Alan H | Common Stock | Grant | Acquire A | No | No | 0 | 6,577 | 0.00 | 7,104,320 |
15 Mar 24 | Auerbach Alan H | Stock Option Common Stock | Grant | Acquire A | No | No | 5 | 9,047 | 45.24 k | 9,047 |
12 Feb 24 | Douglas M Hunt | Common Stock | Grant | Acquire A | No | No | 0 | 37,894 | 0.00 | 141,213 |
12 Feb 24 | Douglas M Hunt | Stock Option Common Stock | Grant | Acquire A | No | No | 6.36 | 52,452 | 333.59 k | 52,452 |
12 Feb 24 | Auerbach Alan H | Common Stock | Grant | Acquire A | No | No | 0 | 160,796 | 0.00 | 7,097,743 |
12 Feb 24 | Auerbach Alan H | Stock Option Common Stock | Grant | Acquire A | No | No | 6.36 | 222,573 | 1.42 mm | 222,573 |
12 Feb 24 | Maximo F Nougues | Common Stock | Grant | Acquire A | No | No | 0 | 43,307 | 0.00 | 171,973 |
12 Feb 24 | Maximo F Nougues | Stock Option Common Stock | Grant | Acquire A | No | No | 6.36 | 59,946 | 381.26 k | 59,946 |
12 Feb 24 | Jeffrey Jerome Ludwig | Common Stock | Grant | Acquire A | No | No | 0 | 27,067 | 0.00 | 127,037 |
12 Feb 24 | Jeffrey Jerome Ludwig | Stock Option Common Stock | Grant | Acquire A | No | No | 6.36 | 37,466 | 238.28 k | 37,466 |
News
10 Health Care Stocks With Whale Alerts In Today's Session
19 Mar 24
HC Wainwright & Co. Maintains Buy on Puma Biotechnology, Lowers Price Target to $7
1 Mar 24
Earnings Scheduled For February 29, 2024
29 Feb 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
14 Feb 24
HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $8 Price Target
13 Feb 24
Press releases
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
18 Apr 24
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
3 Apr 24
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
20 Mar 24
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
27 Feb 24
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
13 Feb 24